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A B S T R A C T
Duration of diabetes and chronic hyperglycemia are the most important risk factors in the pathogenesis of diabetic
retinopathy (DR). However, there is increasing evidence suggesting that genetic factors may also contribute to its develop-
ment. The aim of this study was to determine the role of the HLA system in the development of DR in patients with type 1
diabetes mellitus. Class II genes (DRB1, DQB1) were typed using the PCR-SSP method. Based on the fundus examina-
tion the patients were divided into two groups: one group with no or mild nonproliferative diabetic retinopathy (NPDR)
and the other group with severe/very severe NPDR or proliferative diabetic retinopathy (PDR). The study confirms the in-
fluence of HLA genes in the development of DR in Croatian type 1 diabetic patients. In our patients, susceptibility to PDR
appears to be primarily associated to DQB1*0201 with the relative risk, RR=5.29 and DQB1*0302 (RR=2.84). However,
a strong positive correlation between DR and alles DRB1*0301 (RR=2.12) and DRB1*0402 (RR=3.01) was also found.
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Introduction
Diabetic retinopathy is a common and progressive
complication of diabetes mellitus. It is a leading cause of
acquired blindness in working-age adults and it has been
estimated that it causes 12% of blindness in developed
countries1. Diabetic retinopathy is characterized by the
loss of pericytes, hypertrophy of the basement membrane,
microaneurysms formation, increased vascular permeabil-
ity, capillary occlusions, neovascularisation and fibrovas-
cular proliferation. The predominant cause of visual loss
in diabetic patients results primarily from intraocular
angiogenesis (proliferative diabetic retinopathy, PDR) and
leakage of the retinal vessels (diabetic macular edema,
DME)1,2. According to the Wisconsin epidemiologic study
of diabetic retinopathy (WESDR) in patients with type 1
diabetes mellitus the prevalence of any grade of retino-
pathy after more than 15 years of duration of diabetes was
99.5% and after 35 years 67% of them had proliferative di-
abetic retinopathy (PDR)3. Chronic hyperglycemia and
the duration of diabetes are the most important risk fac-
tors in the development of retinopathy, with strict control
of the blood glucose level preventing and delaying its on-
set and progression4,5. However, in some patients retino-
pathy progresses in a short period of time despite good
glycemic control, whilst others do not develop retinopathy
even in the absence of adequate glycemic control suggest-
ing that certain genetic predisposition may exist. In some
families the risk of PDR development is increased with
the familial clustering of this form of DR which could not
be accounted for with the conventional risk factors6. The
genetic component is further confirmed by twin and popu-
lation studies7–10. It is presumed that genetic influence
may explain 50% of the risk of PDR6.
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Although extensively studied, the pathogenesis of dia-
betic retinopathy is still insufficiently understood, and
the mechanisms leading to blood-retinal barrier disrup-
tion, capillary occlusion and subsequent retinal neovas-
cularisation have still not been completely determined.
There is undeniable evidence however that the immune
system has an active role in its development with a
marked affect of autoimmune mechanisms in its initial
and particularly in its proliferative phases with increas-
ing data suggesting that genetic factors may also play an
important role11–16.
Human leukocyte antigen (HLA) system plays a sig-
nificant role in immune responses and immunologic tol-
erance, and its association to diabetes type 1 is well
recognized17. Hence, the search for markers of a genetic
predisposition for diabetic retinopathy has focused on
genes encoded by the HLA region. There are several
studies investigating the role of different HLA antigens
in development and progression of diabetic retinopathy.
A small number of accomplished studies have revealed
controversial results and have not completely succeeded
to explain the relationship between retinopathy and he-
reditary factors18–30. Development of modern molecular
biology techniques and accessibility of high resolution
HLA gene typing has advanced research addressing the
relationship of the HLA system and different particu-
larly autoimmune diseases. This in turn has also enabled
more precise identification of HLA genes susceptible to
diabetic retinopathy development. More recent studies
have demonstrated that the relationship of HLA complex
and diabetic retinopathy could in fact be determined on
the DNA level31–34.
Accordingly, the aim of this study was to investigate
the immunogenetic profile with high-resolution genotyp-
ing in Croatian type 1 diabetic patients in order to evalu-
ate the association between the HLA system and retino-




The study included 87 unrelated adults of both sexes
with type 1 diabetes mellitus. The main characteristics of
the patients are shown in Table 1. Based on the fundus
examination they were divided into two groups. The first
group (DR–) consisted of 44 patients who have had diabe-
tes for more than 12 years and showed none or mild signs
of nonproliferative diabetic retinopathy (NPDR) on both
eyes. The second group, also named the severe retinopa-
thy group (PDR+), comprised of 43 patients with severe/
very severe NPDR or proliferative diabetic retinopathy
(PDR) in one or both eyes. All patients went through a
complete medical and ophthalmologic examination and
their medical history was noted.
Fundus examination
Each patient partaking in the study underwent a full
ophthalmologic examination. After pupil dilatation with
topical 1% tropicamide detailed fundus examination for
presence of diabetic retinopathy was performed by binoc-
ular indirect ophthalmoscopy using the Goldman three
mirror lens. Assessment was carried out on seven fields
and the diagnosis and pathological retinal findings were
carefully recorded. Fluorescein angiography was perfor-
med on all patients exhibiting signs of diabetic retino-
pathy and retinopathy was graded using the scale modi-
fied from Airlie House grading system, according to
ETDRS (Early Treatment Diabetic Retinopathy Study)
criteria35. The first DR– group (N=44) consisted of pa-
tients who despite a duration of diabetes for more than
12 years had none or only mild signs of nonproliferative
diabetic retinopathy (NPDR) on both eyes. Patients in
the second PDR+ group (N=43) had severe/very severe
nonproliferative diabetic retinopathy (NPDR) or proli-
ferative diabetic retinopathy (PDR) in one or both eyes.
Severe/very severe NPDR was defined by the presence of
severe retinal hemorrhages in four quadrants, and/or ve-
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TABLE 1
BASELINE CHARACTERISTICS OF TYPE 1 DIABETIC PATIENTS WITHOUT SIGNS OF DIABETIC RETINOPATHY (DR– Group)
AND PATIENTS WITH PROLIFERATIVE DIABETIC RETINOPATHY (PDR+ Group)
DR– Group (N=44) PDR+ Group (N=43) p
Women N (%) 24 (54.55) 20 (46.51) NS
Men N (%) 20 (45.45) 23 (53.49) NS
Age (years)* 47.95±13.35 35.49±7.76 <0.0001
Onset of diabetes (years)* 24.41±3.02 18.37±8.96 0.0138
Duration of diabetes (years)* 23.57±9.44 17.37±5.64 0.0004
Insulin dosage (IU/kg)* 0.76±0.18 0.74±0.20 NS
HbA1c (%)* 8.49±1.32 8.26±1.61 NS
BMI (kg/m²)* 24.77±3,80 23.26±2.69 0.0359
Systolic blood pressure (mmHg)* 134.66±17.96 129.30±13.61 NS
Diastolic blood pressure (mmHg)* 82.50±9.37 84.42±10.19 NS
Antihypertensive treatment N (%) 27 (61.36) 22 (51.16) NS
Abbreviations: HbA1c – glycated hemoglobin value, BMI – body mass index, NS – not significant
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nous beading in two quadrants, and/or extensive intra-
retinal microvascular abnormalities (IRMA) in one quad-
rant. PDR was defined by the presence of new vessels on
the disc and/or within 1 disc diameter from the optic disc
(NVD), and/or new vessels elsewhere in the retina (NVE),
and/or preretinal or vitreous hemorrhage.
HLA typing
DNA was extracted from peripheral blood using the
salting out method. The determination of HLA-DRB1
and -DQB1 specificities was performed using the PCR-
-SSP (Polymerase Chain Reaction – Sequence Specific
Primers) method as described by Olerup36. This method
is based on a PCR reaction which contains 50 mg/mL
genomic DNA, 10xPCR buffer, dNTPs, Taq polymerase
and specific primers, and a subsequent electrophoresis
on a 2% agarose gel. Gels were examined under UV illu-
mination and based on the positive reactions pattern, the
HLA specificity was determined. The method allows the
determination of theerteen HLA-DRB1 and seven HLA-
-DQB1 specificities.
Statistical methods
The patients characteristics were compared by using
the Student’s t-test. The obtained p values less than 0.05
were considered significant. Frequencies were compared
by the chi-square test of independence or alternatively
the Fisher exact probability test where appropriate. The
level of significance was set at p<0.0537. Severity of the
correlation of diabetic retinopathy and each antigen (al-
lele, genotype) of HLA was determined by calculating the
relative risk using the Woolf’s method38.
Results
Patient characteristics
The baseline characteristics of the patients with type
1 diabetes without DR (DR-) and patients with severe di-
abetic retinopathy (PDR+) are shown in Table 1. The
mean page in the DR– group was 47.95±13.35 years and
in the PDR+ group 35.49±7.76 years (p<0.0001). The
mean diabetes duration in the DR- group was 23.57±
9.44 years and in the PDR+ group 17.37±5.64 years
(p=0.0004). There were no statistically significant differ-
ences in the blood sugar level control expressed by HbA1c
value (8.26±1.61 IU/kg vs. 8.49±1.32 IU/kg), insulin
dose per kilogram of body weight (0.74±0.20 IU/kg vs.
0.76±0.18 IU/kg) as well as systolic blood pressure
(129.30±13.61 mmHg vs. 134.66±17.96 mmHg) and dia-
stolic blood pressure (84.42±10.19 mmHg vs. 82.50±
9.37 mmHg) between the study groups. There were also
no statistically significant differences in the use of anti-
hypertensive treatment.
HLA typing
The HLA association with diabetic retinopathy was
determined by analyzing the results of low resolution typ-
ing of HLA class II alleles (Table 2 and Table 4) and sub-
typing / high resolution typing of DRB1*03 and DRB1*04
(Table 3) as well as DQB1*02 and DQB1*03 (Table 5) al-
lele frequencies.
The results of low resolution typing of DRB1 alleles in
patients with proliferative diabetic retinopathy compared
with diabetics without signs of retinopathy are shown in
Table 2. In both groups, the most common allele was
HLA-DRB1*03 with a frequency of 38.37% in patients
with PDR and 22.73% in patients without retinopathy.
This difference was statistically significant (p= 0.0378)
with a relative risk of 2.12. The frequency of DRB1*04 al-
lele was significantly more common in the group of dia-
betic patients with proliferative retinopathy (15.91% in
DR- and 34.88% in PDR+ group, p=0.0068) with the rela-
tive risk of 2.83.
The DRB1*0301 was the only DRB1*03 allele found
in both groups after high resolution typing/subtyping
and it was significantly more frequent in PDR+ than
DR– patients with an incidence of 38.37% and 22.73% re-
spectively (p =0.0378 and RR=2.12). Comparing the re-
sults of DRB1*04 allele subtyping five distinct subtypes
namely *0401, *0402, *0404 *0405 and *0408 were de-
tected. The most prevalent in both groups, and also sig-
nificantly more frequent in patients with PDR+ was al-
lele *0401 (22.09% in the PDR+ and 9.09% in the DR–,
p=0.0309). The relative risk was 2.84 (Table 3).
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TABLE 2
FREQUENCY AND STATISTICAL SIGNIFICANCE OF ALLELES
HLA-DRB1*03 AND *04 IN TYPE 1 DIABETIC PATIENTS
WITHOUT SIGNS OF DIABETIC RETINOPATHY (DR– Group) AND








N % N %
03 20 22.73 33 38.37 0.0378
04 14 15.93 30 34.88 0.0068
TABLE 3
FREQUENCY AND STATISTICAL SIGNIFICANCE OF ALLELES
SUBTYPES HLA-DRB1*03 AND *04 IN TYPE 1 DIABETIC
PATIENTS WITHOUT SIGNS OF DIABETIC RETINOPATHY








N % N %
0301 20 22.73 33 38.37 0.0378
0401 8 9.09 19 22.09 0.0309
0401 8 9.09 19 22.09 0.0309
0402 1 1.14 7 8.14 NS
0404 1 1.14 3 3.49 NS
0405 2 2.27 1 1.16 NS
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Analysis of DQB1 allele frequencies is shown in Table
4. In both groups of patients the most common allele was
DQB1*03, with significantly higher frequency (p=0.0474)
in patients with proliferative diabetic retinopathy (47.67%)
as opposed to patients without retinopathy (31.82%)
with a relative risk of 1.95. Alternatively DQB1*02 allele
(45.35% in the PDR+, to 31.82% in the DR-) showed no
statistically significant differences.
In patients with proliferative diabetic retinopathy im-
plementation /use of subtyping DQB1*02 allel only the
DQB1*0201 allele was found. Conversely in the group of
DR– patients two subtypes DQB1*0201 and *0202 were
detected. The frequency of DQB1*0201 allele in PDR pa-
tients was statistically higher than in the group of pa-
tients with no signs of retinopathy (45.35% vs. 21.59%,
p=0.0016) with a relative risk of 3.01. Allele DQB1*0202
was discovered only in the DR– group (10.23%). Subty-
ping of the DQB1*03 allele identified four distinct subty-
pes (*0301–*0304). In diabetic patients with proliferative
retinopathy the most common allele was DQB1*0302
with a frequency of 43.02% and was found to be statisti-
cally significantly higher than in patients without dia-
betic retinopathy with a frequency of 12.5% (p<0.0001).
The relative risk was 5.29. Conversely the frequency of
DQB1*0301 allele in patients with proliferative diabetic
retinopathy was statistically significantly lower compa-
red to patients without retinopathy (3.49%, vs. 14.77%,
p=0.0207) with a relative risk of 0.21 (Table 5).
Discussion
Diabetic retinopathy (DR) is a common and progres-
sive microvascular complication of diabetes and despite
the availability of effective treatment it remains one of
the leading causes of vision impairment and blindness in
working-age adults3. No distinct predisposing factor has
yet been identified and risk factors such as hypertension,
poor metabolic control, nephropathy and triglycerides
level cannot fully explain the development and progres-
sion of this complication of diabetes mellitus39. It has
been established that strict control of glycemia is the
best approach to preventing this complication18. How-
ever, there are certain diabetic patients who develop
retinopathy despite good glycemic control and conversely
others irrespective of poor glucose control do not develop
signs of retinopathy. It is regarded that these differences
could be due to genetic predisposition40–42.
Although the etiopathogenesis of diabetic retinopathy
is still not fully understood, there is undoubtedly an im-
pact of the immune system on its origin and develop-
ment. It is proven that certain autoimmune mechanisms
exist particularly in the occurrence of retinal capillary
occlusions 1and the development of neovascularization.
The presence of antipericite and antiendothelial antibod-
ies in the blood of patients with diabetes indicate a possi-
ble role of autoimmune reactions in the early stages of di-
abetic retinopathy. Infiltration of monocytes, T and B
lymphocytes, fibroblasts, deposits of immunoglobulins,
activated complement components and lymphokines in
retinal neovascular membranes are evidence of autoim-
mune activity in its proliferative phase11–16.
In view of the role of HLA system in immune activity
and tolerance as well as its association with type 1 diabe-
tes, the search for indicators of genetic predisposition for
the development of diabetic retinopathy is focused on the
HLA gene. It is known that patients with type 1 diabetes
are more prone to develop severe diabetic retinopathy
than patients with type 2 diabetes. The cause is not en-
tirely known, but it could at least partially be connected
to the HLA system3. This may therefore indicate that the
genetic factors may influence the susceptibility for devel-
oping severe retinopathy and thus that risk could addi-
tionally be linked to HLA genes6–10.
Studies on the subject of the association of the HLA
system and different autoimmune diseases have been ad-
vanced using the methods of molecular biology and typing
of HLA genes on the DNA level. This has enabled inves-
tigation of the role of certain alleles in the pathogenesis of
specific autoimmune diseases. In contrast to serological
methods, methods of molecular genetics are more precise
whereby the number of undetected alleles is significantly
lower, and the obtained results provide direct insight into
the genetic basis of the disease. To our best knowledge
this is the first report addressing the association between
diabetic retinopathy and the HLA system in Croatian pa-
tients with type 1 diabetes. This form of investigation is
also rare in other populations21–23,25, 26,31,32,34.
It is known that the duration of diabetes and glycemic
control are the most important risk factors in the devel-
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TABLE 4
FREQUENCY AND STATISTICAL SIGNIFICANCE OF ALLELES
HLA-DRB1*02 AND *03 IN TYPE 1 DIABETIC PATIENTS
WITHOUT SIGNS OF DIABETIC RETINOPATHY (DR– Group) AND








N % N %
02 28 31.82 39 45.35 NS
03 28 31.82 41 47.67 0.0474
TABLE 5
FREQUENCY AND STATISTICAL SIGNIFICANCE OF ALLELES
SUBTYPES HLA-DQB1*02 AND *03 IN TYPE 1 DIABETIC
PATIENTS WITHOUT SIGNS OF DIABETIC RETINOPATHY








N % N %
0201 19 21.59 39 45.35 0.0016
0202 9 10.23 0 0.00 0.0069
0301 13 14.77 3 3.49 0.0207
0302 11 12.50 37 43.02 <0.0001
0303 2 2.27 1 1.16 NS
0304 2 2.27 0 0.00 NS
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opment of diabetic retinopathy. To avoid the influence of
the duration of diabetes on the study’s results we com-
pared a group of patients with pronounced signs of dia-
betic retinopathy at an early age with a group consisting
of patients without retinopathy or with initial signs of
nonproliferative retinopathy in which the diabetes lasted
significantly longer. In addition to the duration of diabe-
tes, glucose level is another significant risk factor for de-
veloping diabetic retinopathy and thus improvement of
glycemic control can slow down or even prevent its pro-
gression2–5. The level of glucose control in both groups of
our patients showed no statistically significant differ-
ences, which means that there were no statistical differ-
ences in meanHbA1c values or in the average dose of insu-
lin per kilogram of body weight. Arterial hypertension is
also a well-known risk factor for developing diabetic reti-
nopathy. In our study, there was no statistically significant
difference in blood pressure control in view of systolic and
diastolic pressure or antihypertensive treatment2–5.
There are several studies investigating the role of dif-
ferent HLA antigens in development and progression of
diabetic retinopathy with conflicting results18–34.
Barbosa et al.18 found that patients with proliferative
retinopathy had lower incidence of HLA-B7 and higher
incidence of HLA-B15. Likewise Gray et al.43 found a
lower incidence of HLA-B7 in diabetic patients with
proliferative retinopathy. Furthermore, Dornan et al.19
established that patients with the same mean blood glu-
cose level with retinopathy had a higher incidence of
HLA-DR4 and lower incidence of HLA-DR2 than those
without retinopathy. Cruickhanks et al.23 found that dia-
betics with HLA-DR4 who were negative for HLA-DR3
were five times more likely to have severe retinopathy
than those negative for both antigens. Falck et al.23 stud-
ied 105 Finnish adolescents with type 1 diabetes mellitus
and found a significantly higher prevalence of HLA-DR1
in patients with retinopathy. In patients with type 2 dia-
betes mellitus Birinci et al.24 establish that HLA-DR4
and DQ8 frequencies were higher in patients with non-
proliferative retinopathy than in those with proliferative
retinopathy and HLA-DR7 frequency was higher in pa-
tients with proliferative retinopathy than in nonproli-
ferative cases. Mimura et al.25 in a study of type 1 diabetic
patient found that the frequencies of alleles HLA-B62,
Cw4 and DQ4 as well as haplotype Cw4-DR4-DQ4, were
significantly higher in the patients with proliferative
retinopathy.
Newer and more advanced methods of HLA typing on
the DNA level used in recent studies even enable a more
precise determination of the relationship between dia-
betic retinopathy and HLA. In our study DRB1*0301 was
the only DRB1*03 allele found in all patients. On the ba-
sis of its frequency, we can conclude that the DRB1*0301
allele could be a risk carrier for the development of dia-
betic retinopathy, especially in its proliferative form. The
role of subtypes of DRB1*04 allele was determined by
comparison of the relative frequency of certain DRB1*04
alleles in both patient groups. A comparison of these
groups in respect to DRB1*0401 allele frequency implies
that the DRB1*0401 allele determines susceptibility to
the development of proliferative diabetic retinopathy in
Croatian diabetic patients with type 1 diabetes. Our re-
sults indicate a susceptibility for diabetic retinopathy de-
velopment in allele DQB1*03 carriers whilst a compari-
son of patients with proliferative diabetic retinopathy
and patients without signs of retinopathy, we find no sig-
nificant differences in allele DQB1*02 frequency. The
specific role of distinct DQB1 alleles becomes clearer after
the suptyping (when high resolution typing) of DQB1*02
and *03 alleles is conducted. Analysis of DQB1*02 and
*03 allele subtyping results revealed a significant differ-
ence in the distribution of certain subtypes in the two
study groups. A few of the investigated alleles exhibited a
protective role whilst others susceptibility to the devel-
opment of diabetic retinopathy. Accordingly a carrier of
the DQB1*0201 allele showed susceptibility to the devel-
opment of proliferative diabetic retinopathy whilst the
DQB1*0202 allele exhibited a protective role (RR=0.05).
Examination of DQB1*03 allele subtypes in both groups
of patients showed a correlation between DQB1*0302 al-
lele and the development of an advanced form of diabetic
retinopathy (RR=5.29).
The HLA alleles associated with diabetic retinopathy
in our research were to some extent consistent with
those found in other studies. To our best knowledge,
Agardh et al.32 conducted one of the few studies address-
ing the association of HLA and diabetic retinopathy in
patients with type 1 diabetes using molecular genetics
(PCR-SSOP). They found a difference in the DRB1*0301
allele frequency between the groups of patients with ad-
vanced diabetic retinopathy and patients without retino-
pathy. Further their results confirmed a link between the
DQB1*0201 allele and proliferative diabetic retinopathy.
However, in contradiction to the results of our study they
found no relationship between DRB1*0401 allele and
proliferative diabetic retinopathy development.
Conclusion
Since HLA status established in our patients with
proliferative diabetic retinopathy are generally different
from those related to the onset of type 1 diabetes, we can
conclude that the HLA status may play a certain role in
the development and progression of diabetic retinopathy.
Further, larger prospective studies need to be conducted
to confirm this premise. Our results, in accordance to the
results of some previous studies in other populations indi-
cate a genetic component in the etiology of diabetic retino-
pathy. In addition to the importance of glycemic control,
immunological factors may also play a notable role in the
pathogenesis of this serious diabetic complication. Our re-
search suggests that the genetic factors and genetic inves-
tigations may be useful in predicting the prognosis of
retinopathy in patients with type 1 diabetes mellitus.
Finally, in view of our results it should be emphasized
that high resolution typing is necessary required in order
to ensure more precise findings which in turn enable
greater accuracy in determining the connection of a par-
ticular allele and retinopathy development.
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POVEZANOST SUSTAVA HLA I RAZVOJA RETINOPATIJE U BOLESNIKA S TIPOM 1
[E]ERNE BOLESTI
S A @ E T A K
Trajanje {e}erne bolesti i kroni~na hiperglikemija najva`niji su rizi~ni ~imbenici u razvoju dijabeti~ke retinopatije
(DR). Me|utim, sve je vi{e dokaza da bi u njenom nastanku va`nu ulogu mogla imati i genetska predispozicija. Cilj ovog
istra`ivanja bio je odrediti ulogu HLA sustava u nastanku i razvoju DR u bolesnika s tipom 1 {e}erne bolesti. Geni razreda
II sustava HLA (DRB1, DQB1) odre|eni su metodom lan~ane reakcije polimerazom PCR-SSP. Na osnovu nalaza na o~noj
pozadini bolesnici su bili podijeljeni u dvije skupine: skupinu bolesnika bez znakova dijabeti~ke retinopatije odnosno
minimalnim neproliferativnim promjenama (NPDR) te skupinu bolesnika s proliferativnom dijabeti~kom retinopatijom
(PDR), odnosno uznapredovalim neproliferativnim promjenama. Ovo istra`ivanje potvrdilo je postojanje utjecaja gena
HLA na razvoj DR u hrvatskih dijabeti~ara s tipom 1 {e}erne bolesti. U ispitivanih bolesnika podlo`nost za razvoj dijabe-
ti~ke retinopatije prvenstveno je povezana s alelima DQB1*0201 (relativni rizik, RR=5,29) i DQB1*0302 (RR=2,84), dok
su visoko podlo`ni, ali uz manje izra`en relativni rizik, aleli DRB1*0301 (RR=2,12) and DRB1*0402 (RR=3,01).
S. Ka{telan et al.: HLA and Diabetic Retinopathy, Coll. Antropol. 37 (2013) Suppl. 1: 65–70
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